IRVINE, Calif.--(BUSINESS WIRE)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Momenta Pharmaceuticals, Inc. (“Momenta” or the “Company”) (Nasdaq: MNTA) concerning possible violations of federal securities laws.
If you purchased shares of Momenta and want more information free of charge, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
On February 17, 2017, Momenta revealed that a contracted Pfizer facility used to manufacture the Company's Glatopa product was sent a warning letter from the U.S. Food and Drug Administration ("FDA"). Momenta's Abbreviated New Drug Application for its Glatopa 40 mg product candidate is under regulatory review, and under FDA policy, final approval depends on the outcome of the compliance observations at the Pfizer manufacturing facility.
On February 20, 2017, a Leerink Capital Partners LLC analyst stated that the FDA warning letter raises concerns for the Company, as manufacturing warning letters can take years to fix, and that a lengthy delay could weaken Momenta's market opportunity for Glatopa.
When this information was revealed to investors, the value of Momenta fell, causing investors serious harm.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.
This press release may constitute Attorney Advertising in some jurisdictions.